Some of the most enticing commercial opportunities for biosimilar manufacturers and the biggest potential savings to the US health system are approaching in the next three years, and drug makers and other stakeholders are laying the groundwork now for that expansion.
The next wave of biosimilars is expected to prove more competitive than the initial wave, posing new challenges for biosimilar...






